NO20055243L - Interferon beta ved alvorlig akutt respiratorisk syndrom (SARS) - Google Patents

Interferon beta ved alvorlig akutt respiratorisk syndrom (SARS)

Info

Publication number
NO20055243L
NO20055243L NO20055243A NO20055243A NO20055243L NO 20055243 L NO20055243 L NO 20055243L NO 20055243 A NO20055243 A NO 20055243A NO 20055243 A NO20055243 A NO 20055243A NO 20055243 L NO20055243 L NO 20055243L
Authority
NO
Norway
Prior art keywords
sars
acute respiratory
respiratory syndrome
severe acute
interferon beta
Prior art date
Application number
NO20055243A
Other languages
English (en)
Norwegian (no)
Inventor
Giampiero De Luca
Original Assignee
Ares Trading Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ares Trading Sa filed Critical Ares Trading Sa
Publication of NO20055243L publication Critical patent/NO20055243L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20055243A 2003-04-17 2005-11-08 Interferon beta ved alvorlig akutt respiratorisk syndrom (SARS) NO20055243L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03101066 2003-04-17
PCT/EP2004/050456 WO2004091653A1 (en) 2003-04-17 2004-04-06 Interferon beta in severe acute respiratory syndrome (sars)

Publications (1)

Publication Number Publication Date
NO20055243L true NO20055243L (no) 2005-11-08

Family

ID=33185950

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20055243A NO20055243L (no) 2003-04-17 2005-11-08 Interferon beta ved alvorlig akutt respiratorisk syndrom (SARS)

Country Status (13)

Country Link
US (1) US20070026014A1 (pt)
EP (1) EP1613342A1 (pt)
JP (1) JP2006523655A (pt)
KR (1) KR20050112127A (pt)
CN (1) CN1798572A (pt)
AU (1) AU2004229185A1 (pt)
BR (1) BRPI0409484A (pt)
CA (1) CA2521650A1 (pt)
EA (1) EA008766B1 (pt)
MX (1) MXPA05011170A (pt)
NO (1) NO20055243L (pt)
UA (1) UA81481C2 (pt)
WO (1) WO2004091653A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2520148A1 (en) * 2003-04-01 2004-12-23 Intermune, Inc. Compositions and methods for treating coronavirus infection and sars
CA2527711A1 (en) * 2003-06-09 2004-12-16 Genome Institute Of Singapore Inhibition of sars coronavirus infection with clinically approved antiviral drugs
US9295669B2 (en) 2010-12-14 2016-03-29 Hoffman La-Roche Inc. Combination therapy for proliferative disorders
US20230201309A1 (en) * 2020-03-27 2023-06-29 Vectura Limited Compositions for the treatment of a respiratory condition
US20220125661A1 (en) * 2020-10-22 2022-04-28 Jacob Waterman Patient-Worn Therapeutic Apparatus

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5723125A (en) * 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
TWI277424B (en) * 1998-05-15 2007-04-01 Schering Corp Combination therapy for eradicating detectable NCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
JP2002220343A (ja) * 2001-01-26 2002-08-09 Toray Ind Inc びまん性肺疾患延命剤
WO2003031587A2 (en) * 2001-10-09 2003-04-17 The Regents Of The University Of California Use of stat-6 inhibitors as therapeutic agents
US20060035859A1 (en) * 2003-05-16 2006-02-16 Hemispherx Biopharma Treating severe and acute viral infections
WO2005009337A2 (en) * 2003-05-16 2005-02-03 Hemispherx Biopharma Treating severe acute respiratory syndrome

Also Published As

Publication number Publication date
BRPI0409484A (pt) 2006-05-02
WO2004091653A1 (en) 2004-10-28
EA008766B1 (ru) 2007-08-31
EA200501625A1 (ru) 2006-04-28
CA2521650A1 (en) 2004-10-28
MXPA05011170A (es) 2005-12-14
US20070026014A1 (en) 2007-02-01
KR20050112127A (ko) 2005-11-29
JP2006523655A (ja) 2006-10-19
UA81481C2 (en) 2008-01-10
CN1798572A (zh) 2006-07-05
AU2004229185A1 (en) 2004-10-28
EP1613342A1 (en) 2006-01-11

Similar Documents

Publication Publication Date Title
EE05065B1 (et) Karbamiidasendatud imidasokinoliinid, nende kasutamine raviks ja neid sisaldavad farmatseutilised preparaadid
IL171972A0 (en) Compositions and methods for treatment of severe acute respiratory syndrome(sars)
TW200733953A (en) Materials and methods for treating viral infections
NO20006328D0 (no) Attenuerte negative trådvirus med endret interferonantagonistaktivitet for anvendelse som vaksiner og medikamenter
NO20073632L (no) Behandling av hepatitt C med interferon-beta i en asiatisk populasjon
NO20065860L (no) Stabiliserte flytende interferonformuleringer
ATE476983T1 (de) Immunostimulierende polynukleotide sequenzen zur verwendung bei der verhinderung und behandlung von viralen erkrankungen der atemwege
BR0011433B1 (pt) Compostos de imidazoquinolinas substituídas com sulfonamida e sulfamida e composição farmaceutica cotendo os mesmos
HUP0103423A2 (hu) Ribavirint és alfa-interferont tartalmazó kombinált terápia vírusellenes kezelésben nem részesült, krónikus hepatitis C fertőzött paciensek kezelésében
NO20061912L (no) Vaksinesammensetninger omfattende et interleukin 18 og saponin adjuvant system
WO2005023290A3 (en) Uses of interferons for the treatment of severe acute respiratory syndrome and other viral infections
PL371736A1 (en) Method for administering glp-1 molecules
NO20055243L (no) Interferon beta ved alvorlig akutt respiratorisk syndrom (SARS)
TW200633995A (en) Andrographolide derivatives to treat viral infections
NO20053348L (no) Farmasoytisk sammensetning for behandling av virusangrep.
HUP0202502A2 (hu) Virális fertőzőképességet blokkoló peptidek és eljárások ezek alkalmazására
DK1423168T3 (da) Farmaceutisk præparat omfattende gabapentin eller en analog deraf og et alfa-aminoamid og dets analgetiske anvendelse
TW200517107A (en) Novel formulation
ATE546151T1 (de) Verwendung von hcg-fragmente enthaltene zusammensetzungen zur mukosalen und oralen anwendung
WO2007057436A3 (en) Interferon in influenza
NO20055512L (no) Terapi eller prevensjon av respiratoriske, virale infeksjoner med alfa-tyimosinpeptider
WO2004089983A3 (en) Severe acute respiratory syndrome (sars) causing coronavirus
BR9916893A (pt) Tratamento
NO20035056D0 (no) Adenosinanaloger for behandling av insulinresistenssyndrom og diabetes
HUP0202931A2 (hu) Egy gyógyszerészetileg hatásos összetétel és a beadására szolgáló készülék

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application